An ambitious effort to develop Spanish universities into campuses that are among Europe’s best has stoked some long-standing regional rivalries.
On 26 November, the government announced which universities would benefit from the inaugural round of an annual programme called the Campus of International Excellence, administered jointly by the Ministry of Science and Innovation and the Ministry of Education. The €150-million (US$226-million) scheme is designed to steer resources, in the form of government seed money and loans, to the strategic infrastructure projects with the most potential to aid teaching and research.
Read the entire news story on Nature.com [html] or here [pdf]
This past July, the European Commission released estimates that if generic drugs were to enter markets immediately after patents expire—instead of the present average of seven months later—EU patients and national health services might save €3 billion ($4.5 billion) annually. But regulators acknowledge that costly and time-consuming patent disputes, and possible anticompetitive practices in the pharmaceutical industry, mean that such savings remain elusive. Continue reading Sluggish generics entry prompts calls for European patent reform→
Like most stem cell biologists, Helen Mardon obtained her first cell lines from someone she knew. Later, when she needed more material, she chose to pay for a line from a commercial dealer. Eventually, the Oxford Stem Cell Institute co-director derived her own in-house human embryonic stem cell core from embryos donated by in vitro fertilization patients.
Mardon could have gotten human embryonic stem cell (hESC) lines for the cost of delivery from the UK Stem Cell Bank (SCB), one of a handful of stem cells banks worldwide (See A bank in England for stem cells). Supported by government funds, the bank stores, distributes and provides ethical oversight of hESC lines in Britain free of charge to academic and commercial researchers. The samples they distribute are top notch: a half-dozen bench researchers screen their stocks to ensure banked lines are free from viral infections or mycoplasma contamination, and routine checks are also completed before lines are shipped. But for now, Mardon says, “going through the bank just adds a huge layer of paperwork and bureaucracy”.
I covered monkey business of several types this week. First, I wrote a news story about Simon Singh, who announced that he hopes to appeal a judge’s ruling in a libel case about chiropractic. He and his supporters are also campaigning to limit the influence of English libel laws on public science-related debates.
I also wrote a news story about scientists who tickled apes and human babies so they could see how ape laughter reflects our evolutionary relationships.
Finally I blogged briefly about a topic that’s gotten attention in the media: the failure of the American health care insurance system to adequately protect Americans from financial ruin.
Journalist covering global development by way of science and technology.
An ambitious effort to develop Spanish universities into campuses that are among Europe’s best has stoked some long-standing regional rivalries.
This past July, the European Commission released estimates that if generic drugs were to enter markets immediately after patents expire—instead of the present average of seven months later—EU patients and national health services might save €3 billion ($4.5 billion) annually. But regulators acknowledge that costly and time-consuming patent disputes, and possible anticompetitive practices in the pharmaceutical industry, mean that such savings remain elusive. 
I covered monkey business of several types this week. First, I wrote a